|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutation of BRAF V600E was pronounced in HCL, but "hairiness" was not linked to the mutation.
|
31538423 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The intestinal lymphoma bears the BRAF V600E mutant, which is the molecular hallmark of HCL, being implicated in its pathogenesis.
|
31354304 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PCR and IHC were cheaper and identified V600E in 100 % of HCL cases.
|
30872385 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identification of the BRAF-V600E kinase mutation as the genetic cause of HCL has opened the way, in the relapsed/refractory experimental setting, to targeted and non-myelotoxic effective strategies that are based on inhibition of BRAF with vemurafenib, co-inhibition of BRAF and its target MEK with dabrafenib and trametinib, and BRAF inhibition with vemurafenib combined with anti-CD20 immunotherapy.
|
31187521 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Areas covered: Herein the authors review the role of BRAF V600E and RAF-MEK-ERK signaling in the pathogenesis of HCL, anecdotal clinical reports of BRAF inhibitor monotherapy in management of relapsed or refractory HCL, larger phase 2 trials investigating efficacy of BRAF inhibitor therapy for HCL, adverse effects commonly associated with BRAF inhibitor therapy, including cutaneous toxicity, and mechanisms of therapeutic resistance.
|
30782032 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PCR and IHC were cheaper and identified V600E in 100 % of HCL cases.
|
30872385 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Areas covered: Herein the authors review the role of BRAF V600E and RAF-MEK-ERK signaling in the pathogenesis of HCL, anecdotal clinical reports of BRAF inhibitor monotherapy in management of relapsed or refractory HCL, larger phase 2 trials investigating efficacy of BRAF inhibitor therapy for HCL, adverse effects commonly associated with BRAF inhibitor therapy, including cutaneous toxicity, and mechanisms of therapeutic resistance.
|
30782032 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The intestinal lymphoma bears the BRAF V600E mutant, which is the molecular hallmark of HCL, being implicated in its pathogenesis.
|
31354304 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identification of the BRAF-V600E kinase mutation as the genetic cause of HCL has opened the way, in the relapsed/refractory experimental setting, to targeted and non-myelotoxic effective strategies that are based on inhibition of BRAF with vemurafenib, co-inhibition of BRAF and its target MEK with dabrafenib and trametinib, and BRAF inhibition with vemurafenib combined with anti-CD20 immunotherapy.
|
31187521 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutation of BRAF V600E was pronounced in HCL, but "hairiness" was not linked to the mutation.
|
31538423 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing.
|
29238890 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Many such genetic events have already demonstrated clinical utility, such as BRAF V600E that confers sensitivity to vemurafenib in patients with hairy cell leukemia.
|
29702524 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hairy cell leukemia (HCL) is a rare, low-grade mature B-cell neoplasm with a characteristic clinical, morphological, immunophenotypic, and more recently described molecular (BRAF p.V600E mutation) profile.
|
30197362 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing.
|
29238890 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Many such genetic events have already demonstrated clinical utility, such as BRAF V600E that confers sensitivity to vemurafenib in patients with hairy cell leukemia.
|
29702524 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hairy cell leukemia (HCL) is a rare, low-grade mature B-cell neoplasm with a characteristic clinical, morphological, immunophenotypic, and more recently described molecular (BRAF p.V600E mutation) profile.
|
30197362 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recently, the BRAF V600E mutation was identified in most patients with classical HCL, resulting in constitutive mitogen-activated protein kinase pathway activation; impressive responses are achieved in heavily pre-treated patients with BRAF inhibition.
|
28146266 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAF V600E somatic mutation.
|
29110361 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Accompanying mutations of the KLF2 transcription factor or the CDKN1B/p27 cell cycle inhibitor are recurrent in 16% of patients with HCL and likely cooperate with BRAF-V600E in HCL pathogenesis.
|
28297625 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Accompanying mutations of the KLF2 transcription factor or the CDKN1B/p27 cell cycle inhibitor are recurrent in 16% of patients with HCL and likely cooperate with BRAF-V600E in HCL pathogenesis.
|
28297625 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAF V600E somatic mutation.
|
29110361 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recently, the BRAF V600E mutation was identified in most patients with classical HCL, resulting in constitutive mitogen-activated protein kinase pathway activation; impressive responses are achieved in heavily pre-treated patients with BRAF inhibition.
|
28146266 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Sensitive molecular assays for detecting BRAF V600E allow HCL (highly responsive to purine analogs) to be better distinguished from HCL-like disorders, which are treated differently.
|
27554081 |
2016 |